China PharmaHub Corp.

CIK:0001462109|SEC Filings

Statements of Operations (Unaudited) (USD $)	3 Months Ended		33 Months Ended
Statements of Operations (Unaudited) (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Income Statement [Abstract]
Revenue	$ 41,840	$ 0	$ 41,840
Cost of goods	33,521	0	33,521
Gross profit	8,319	0	8,319
Operating expenses
General and administrative	49,346	60,892	500,548
Professional fees	14,436	153,630	882,347
Depreciation expense	1,246	1,119	7,153
Total operating expenses	65,028	215,641	1,390,048
Other (income) expenses
Gain on foreign currency transaction	0	27,835	37,644
Interest expense	(421)	0	(1,906)
Other income	29	0	5,247
Bad debt expense	(923)	0	(41,273)
Loss on equity investments	(42)	(5,637)	(38,118)
Total other income/(expenses)	(1,357)	22,198	(38,406)
Net Loss before noncontrolling interest	(58,066)	(193,443)	(1,420,135)
Noncontrolling interest	(17)	(513)	(1,350)
Net Loss - attributable to China Pharmahub Corp.	$ (58,049)	$ (192,930)	$ (1,408,785)
Loss per common share - basic and diluted	$ 0.00	$ (0.01)
Weighted-average shares outstanding - basic and diluted	16,617,483	16,482,099

Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		33 Months Ended
Statements of Cash Flows (Unaudited) (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Cash flows from operating activities:
Net loss	$ (58,066)	$ (193,443)	$ (1,420,135)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,246	1,119	7,153
Common stock issued for services	0	33,315	447,540
Loss on equity investments	42	5,637	38,118
Net changes in assets and liabilities:
Deposit	0	0	(3,544)
Prepaid expenses	(3,003)	2,641	(3,003)
Accounts receivable	(14,568)	0	(14,568)
Other receivable	0	(22,105)	0
Other receivable - related party	951	0	(22,907)
Inventory	6,228	0	(13,225)
Loan from shareholder advances	(5,343)	0	5,422
Accounts Payable and accrued expenses	36,073	19,455	248,375
Other current liabilities	6,287	(1,131)	7,522
Net cash used in operating activities	(30,153)	(154,513)	(723,252)
Cash flows from investing activities:
Equipment purchases	0	0	(24,920)
Investment in Equity Investments	0	0	(65,288)
Net cash used in investing activities	0	0	(90,208)
Cash flows from financing activities:
Purchase of World Wide Relics	0	0	(275,250)
Proceeds from sale of escrowed shares	0	0	2,871
Repurchase of escrowed shares	0	(1,069)	(1,250)
Noncontrolling Interest	0	800	800
Proceeds from sale common stock	0	0	1,242,395
Net cash (used in) provided by financing activities	0	(269)	969,566
Net (decrease) increase in cash and cash equivalents	(30,153)	(154,782)	156,106
Cash and cash equivalents - beginning of period	186,259	640,773
Cash and cash equivalents - end of period	156,106	485,991	156,106
Non-cash financing and investing activities:
Issuance of common shares to acquire equity investment	$ 0	$ 0	$ 1,476

Balance Sheets (Unaudited) (USD $)	Mar. 31, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$ 156,106	$ 186,259
Deposit	3,544	3,544
Prepaid expenses	3,003	0
Accounts receivable	14,568	0
Other receivable - related party	22,907	23,858
Inventory	13,225	19,453
Total current assets	213,353	233,114
Equity Investments	28,646	28,688
Equipment, net	17,767	19,013
Total Assets	259,766	280,815
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payables and accrued expenses	243,375	207,302
Loan from related parties	5,422	10,765
Other current liabilities	7,522	1,235
Total current liabilities	256,319	219,302
STOCKHOLDERS' EQUITY
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.001 par value, 100,000,000 shares authorized, 17,069,547 and 17,694,547 issued and 16,643,459 and 16,537,155 oustanding, respectively	17,072	17,072
Additional paid-in-capital	1,405,710	1,405,710
Noncontrolling interest	(550)	(533)
Deficit accumulated during the development stage	(1,418,785)	(1,360,736)
Total stockholders' equity	3,447	61,513
Total	$ 259,766	$ 280,815